Verona Pharma Plc ADR (NASDAQ:VRNA) shares, rose in value on Thursday, May 08, with the stock price down by -4.17% to the previous day’s close as strong demand from buyers drove the stock to $66.26.
Actively observing the price movement in the last trading, the stock closed the session at $69.14. Referring to stock’s 52-week performance, its high was $74.18, and the low was $11.39. On the whole, VRNA has fluctuated by 22.32% over the past month.
With the market capitalization of Verona Pharma Plc ADR currently standing at about $5.64 billion, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 305.62M, with a low estimate of 61.92M and a high estimate of 72.74M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 68.17M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRNA’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of VRNA currently trading nearly 2.13% and 3.59% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.57, while the 7-day volatility ratio is showing 4.44% which for the 30-day chart, stands at 5.94%. Furthermore, Verona Pharma Plc ADR (VRNA)’s beta value is 0.19, and its average true range (ATR) is 3.59.
A comparison of Verona Pharma Plc ADR (VRNA) with its peers suggests the former has fared considerably weaker in the market. VRNA showed an intraday change of -4.17% in last session, and over the past year, it grew by 343.21%%.
Data on historical trading for Verona Pharma Plc ADR (NASDAQ:VRNA) indicates that the trading volumes over the past 3 months, they’ve averaged 1.44 million. According to company’s latest data on outstanding shares, there are 85.13 million shares outstanding.
Nearly 12.34% of Verona Pharma Plc ADR’s shares belong to company insiders and institutional investors own 71.00% of the company’s shares. The stock has risen by 42.68% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRNA stock heading into the next quarter.
